Corporate Development

Corporate Development

As a leader in sleep medicine and with a growing hematology/oncology portfolio, we are developing meaningful medicines and bringing them to people with unaddressed needs around the world. We work to expand the science behind our medicines, acquire new therapies that will make a difference in patients’ lives, and partner to develop early-stage or later-stage molecules with great potential – reaffirming our commitment to patients with each decision. We seek solutions for rare or complex diseases, and we help ensure those solutions are available for the often-overlooked patients who need them.

Our Approach

One of the key components of our growth strategy is ongoing corporate development. Our team actively seeks opportunities to acquire or in-license development-stage (both preclinical and clinical), near-commercial and commercial products that are highly differentiated.

Facts & Figures

Sleep

  • We acquired and made available the first FDA-approved treatment for narcolepsy with cataplexy – a life-long disorder causing excessive sleepiness and muscle weakness; and continue to focus on development of options for narcolepsy patients with excessive sleepiness.

Hematology/Oncology

  • We developed the first new treatment in more than 40 years for adults with two types of high-risk acute myeloid leukemia (AML);
  • For patients with acute lymphoblastic leukemia (ALL), we launched the first solution for those who have developed hypersensitivity to E. coli-derived asparaginase – a severe reaction to other therapies; and
  • We introduced the only option on the market for helping both adults and children recover from rare, life-threatening complication of stem cell transplants.

Areas of Interest

  • Hematology/oncology + adjacencies
  • Sleep + adjacencies
  • Other therapeutic areas

Contact Corporate Development & Partnering